Dr. Saxena on the Importance of Initial Treatment Selection in ALK+ NSCLC

Video

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, assistant attending physician, NewYork-Presbyterian Hospital, assistant professor of medicine, Weill Cornell Medical College, discusses the importance of initial therapy selection in ALK-positive non­—small cell lung cancer (NSCLC).

Patients will eventually develop resistance to ALK inhibitors, says Saxena. Secondary mutations may develop as a result of insufficient suppression of ALK or bypass pathways.

Specific secondary mutations that may arise following treatment with crizotinib (Xalkori) or alectinib (Alecensa) are sensitive to next-generation agents such as brigatinib (Alunbrig) and lorlatinib (Lorbrena).

As such, optimizing first-line treatment selection is necessary as it may influence which agents are available to the patient upon disease progression, concludes Saxena.

Recent Videos
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Brian Kim, MBA, the chief executive officer of Mission Bio
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Ben Samelson-Jones, MD, PhD, an assistant professor of pediatric hematology at Perelman School of Medicine, University of Pennsylvania, and the associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Roger Hajjar, MD, the director of the GCTI
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development
© 2025 MJH Life Sciences

All rights reserved.